Will
12 Oct 2018
Great results [link] Great results again, but the share price fell. I guess a p/e of 30 was just too much.
Hardboy
30 Mar 2018
Volume 51k shares traded on Thursday. For Bioventix that's huge!
smilingmickey1
28 Mar 2018
Re: Interims Hello Hardboy,NIce to find £770k due from previous years underpayment of royalties. Royalty deals usually have some form of procedure for post period auditing to avoid underpayment. This makes a big difference to the cash holding going forward, securing the divi for the coming year.The report sounds much more positive than recent prececessors , with optimism that the Siemens revenue would be commencing in 2018, together with good progress being made on some other exciting research projects.
Hardboy
26 Mar 2018
Interims Don't see anything not to like about them.Keep it up!
smilingmickey1
07 Feb 2018
Re: AGM Sorry for delay in reply. Re your question about price weakness, there has not been a business update for a while. Bioventix business highly dependent upon take up of Siemens kit by health professionals. Not in Bioventix hands. This business is highly profitable, but it is priced in for growth!SM
Hardboy
02 Feb 2018
Today Very high volume & big drop. Anyone know why?
Hardboy
20 Jan 2018
Re: AGM Sorry Mickey, I had intended to go, but something came up at the last minute which prevented me. I can't remember what it was. Maybe next year.
smilingmickey1
19 Jan 2018
Re: AGM I know it,s a while ago Hardboybut did you attend AGM? Anything of interest.SM
Hardboy
11 Dec 2017
AGM Subject to weather I am hoping to go to the AGM on Thursday. Anyone else planning to be there?
Hardboy
26 Oct 2017
xd It's unusual to see a rise like that on a day of no news and the share going ex div
smilingmickey1
17 Oct 2017
Great results A great set of financials, as previously guided. Healthy dividend pay out including a special divi, gives an annualised payout of around 3.5%, based on current share price. A business with sales revenue up by 30+% with no cost increase is certainly an attractive animal.It would appear that use of the Siemens kit have not taken off yet and the level of growth in sales of this diagnostic test in the coming year will influence whether the overall BVXP growth can be sustained.
smilingmickey1
26 Sep 2017
Re: Today's rise Results are due to be published on 17th October. They should be quite spectacular to those who are not following closely!
Hardboy
25 Sep 2017
Today's rise Looking at today's rise & the trades I'm assuming there has been some press comment about them over the weekend.
charlie51
05 Sep 2017
Re: Trading update Revenue to 30th June 2017 is expected to be “marginally in excess” of £7m and that due to the cost base “follow a similar shallow trajectory as in previous years”, both revenues and profits are expected to be ahead of market expectations. ShareScope and Stockopedia forecasts were for revenue of £6.3m and pre-tax profits of £4.9m. In excess of £7M is a considerable hike on top of the forecasts - in excess of 11% as the precise figure above the £7M not yet known. One could assume pre-tax profits and earnings per share to be well ahead and significantly more than expectations - possibly circa 30% rather than the 17% forecast. The implications for the cash pile and dividend are clear.Going forward given that they described the launch of a new test by Siemens for troponin, a key biomarker used in heart attack diagnostics, as ‘significant' for the company and that this was announced early in May so has had only a matter of weeks to make contributions to the FY ending 30 June this augurs well for the current year when it will contribute for the full 52 weeks.A good place to be ‘in’ in my view.
Hardboy
04 Sep 2017
Re: Trading update SM, Quite right, as long as they keep increasing revenue, profits and dividend, the share price is a bit of an irrelevance to me - at least till it starts getting to be too large a proportion of my portfolio.
